CNBC's Stock Pops & Drops From October 10

, Guy Adami said that it is all right to own

even after Friday's 35.76 percent spike. He added that typically in these situations traders should lower exposure. The stock traded higher on the news that its colon cancer screening test will be covered by Medicare.

dropped 6.81 percent on a downgrade by an analyst at Craig Hallum. Pete Najarian thinks that there are so many other names traders should by now, other than

.

(ADR)

jumped 1.18 percent after

added it to its conviction buy list. Steve Grasso said that the stock is trading below its 200-day moving average and the last time it failed to break above it. Grasso thinks that it will break the $107 price level and that the stock is a buy.

gained 8 percent on its debut on the New York Stock Exchange. Brian Kelly said that he usually doesn't trade stocks without one month of trading data. He thinks that Friday's low might be used as a stop loss.